Efficacy and safety of GLP-1 receptor agonists in patients with schizophrenia spectrum disorders treated with antipsychotics: a systematic review and meta-analysis.
Weight gain and impaired glucose metabolism are common complications of antipsychotic treatment in schizophrenia spectrum disorders (SSD). While beneficial in other populations, the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in SSD remain unclear. We conducted a systematic review and m...